From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Bismuth subgallate, a hemostatic agent, acts on coagulationfactor XII (Hageman factor), leading to the activation of the coagulation cascade and improving early formation of a fibrin clot .
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
Turoctocog alfa is a recombinant coagulationfactor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa can be used for researching haemophilia A .
Denecimig (Mim8) is a novel activated coagulationfactor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
Human Factor XIa is a blood coagulation protease. Human Factor XIa activates the Factor IX and Factor V, resulting in the generation of thrombin and fibrin .
Human Factor XIIa Beta is the active fragment of coagulationfactor XII, that participates in the intrinsic pathway of coagulation, and leads to the formation of blood clots. Human Factor XIIa Beta also participates in the kinin-generating pathway, which leads to the release of bradykinin (vasodilator). Human Factor XIIa Beta stimulates the release of catecholamines, and mediates its cardiovascular effects through a noncholinergic angiotensin-converting enzyme (ACE)-regulated mechanism .
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulationfactors, osteocalcin and matrix-Gla protein.
Human Factor Alpha XIIa is a blood coagulation protease, which increases the clotting potential. Human Factor Alpha XIIa exhibits a fibrinolysis protein homologous heavy chain, indicating its function in fibrinolysis .
Human Factor VIIa is a vitamin K-dependent serine protease that is involved in the blood coagulation process. Human Factor VIIa activates Factor X, which causes the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, leading to the formation of blood clots. Human Factor VIIa exhibits the potential to ameliorate Hemophilia .
Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
Bovine Factor IXa Beta is an inactive and highly specific enzyme, with a minimal extended substrate recognition site and a preference for particular amino acid residues at specific subsites. Bovine Factor IXa Beta plays a role in the blood coagulation cascade .
Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
EMD 495235 is a potent and orally active coagulationfactor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities .
Frunexian (EP-7041) is a selective and potent inhibitor of coagulationfactor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .
AS1468240 is an orally active inhibitor for anticoagulant factor Xa (fXa), that inhibits human fXa with IC50 of 8.7 nM. AS1468240 prolongs the coagulation time in mice .
Bovine Factor XIa is an enzyme, which is involved in the intrinsic pathway of blood coagulation. Bovine Factor XIa is highly selective and exhibits a minimal extended substrate recognition site of at least five residues long. Bovine Factor XIa is reactive as Bovine Factor IXa (HY-E70393I) does, that it cleaves all the peptides bearing factor IX activation site sequences .
Bovine fibrinogen (from fibrinogen) is a native fibrinogen from bovine plasma. Bovine fibrinogen (from fibrinogen) can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 .
Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulationfactors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa .
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called CoagulationFactor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).
Asundexian (BAY 2433334) is an orally active coagulationfactor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulationfactors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Dextran sulfate sodium salt (MW 450000-550000) is a polymer of anhydroglucose with a molecular weight range of 450000-550000. Dextran sulfate sodium salt (MW 450000-550000) can effectively enrich precipitated cells and can be used to isolate neutrophils from human and rat blood. Dextran sulfate sodium salt (average MW 500000) can effectively enhance the conversion activity of coagulationfactor XIIa (FXIIa) to induce hepatocyte growth factor (HGF) and increase the specific activity of FXIIa.
Elastase, Human leukocytes is a serine protease present in the nitrogen-loving granules of neutrophils. Elastase, Human leukocytes potential substrates include almost all components of the extracellular matrix, as well as a variety of proteins such as coagulationfactors, complement, immunoglobulins and cytokines. It has a strong proteolytic function and participates in the pathogenesis of inflammatory tissue damage .
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulationfactor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
FXIIa-IN-5 (Compound 4J) is an orally active, selective inhibitor for factor XIIa (FXIIa), with IC50 of 21 nM. FXIIa-IN-5 inhibits the intrinsic coagulation pathways, and exhibits anti-inflammatory and antithrombotic activity in Carrageenan (HY-125474)-induced mice thrombosis models. FXIIa-IN-5 exhibits moderate pharmacokinetic characteristics and slightly toxicity (at 100 mg/kg) .
Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .
Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulationfactor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
Bovine fibrinogen (from fibrinogen) is a native fibrinogen from bovine plasma. Bovine fibrinogen (from fibrinogen) can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 .
E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulationfactor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases .
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called CoagulationFactor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
Denecimig (Mim8) is a novel activated coagulationfactor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulationfactors, osteocalcin and matrix-Gla protein.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (His) is the recombinant pig-derived Coagulation Factor XII/F12 protein, expressed by E. coli , with N-6*His labeled tag. The total length of Coagulation Factor XII/F12 Protein, Pig (His) is 352 a.a., with molecular weight of ~43.8 kDa.
Factor IX (F9) is a vitamin K-dependent plasma protein that plays a critical role in the intrinsic pathway of coagulation. Factor IX coordinates the conversion of factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation factor IX/F9 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor IX/F9 protein, expressed by HEK293 , with C-6*His labeled tag.
Coagulation Factor II/F2, also known as thrombin, functions as a pivotal serine protease. Its enzymatic action involves cleaving bonds after Arg and Lys residues, facilitating the conversion of fibrinogen to fibrin. Thrombin additionally activates key factors like V, VII, VIII, XIII, and, in conjunction with thrombomodulin, protein C. Beyond blood homeostasis, thrombin plays a role in inflammation and the complex dynamics of wound healing. Coagulation Factor II/F2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor II/F2 protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor II/F2 Protein, Mouse (HEK293, His) is 594 a.a., with molecular weight of ~85 kDa.
The factor II/F2 protein (also known as thrombin) plays a key role in blood homeostasis, inflammation, and wound healing. As a multifunctional enzyme, it catalyzes the conversion of fibrinogen into fibrin to form the coagulation network. Coagulation Factor II/F2 Protein, Rat (HEK293, His) is the recombinant rat-derived Coagulation Factor II/F2 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation Factor VII (F7) protein lacks crucial conserved residue(s) needed for propagating feature annotation. Coagulation Factor VII/F7 Protein, Mouse (CHO, His) is the recombinant mouse-derived Coagulation Factor VII/F7 protein, expressed by CHO , with C-His labeled tag. The total length of Coagulation Factor VII/F7 Protein, Mouse (CHO, His) is 422 a.a., with molecular weight of 56-63 kDa.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Human (His) is the recombinant human-derived Coagulation Factor XI/F11 protein, expressed by E. coli , with N-6*His labeled tag.
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation Factor VII/F7 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor VII/F7 protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor VII/F7 Protein, Human (HEK293, His) is 406 a.a., with molecular weight of ~50 kDa.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (P. pastoris, His) is the recombinant pig-derived F12/Coagulation Factor XII, Pig, expressed by P. pastoris , with N-6*His labeled tag.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XI/F11 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (His-SUMO) is the recombinant human-derived Coagulation factor VII/F7 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Coagulation Factor X/F10 Protein, a crucial vitamin K-dependent glycoprotein, is central to blood clotting. It produces Factor Xa, essential for converting prothrombin to thrombin, a process facilitated by factor Va, calcium, and phospholipid in the intricate cascade of blood coagulation. Coagulation Factor X/F10 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor X/F10 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Coagulation Factor X/F10 Protein, Mouse (HEK293, His) is 461 a.a., with molecular weight of ~55.0 kDa.
Factor X (F10) is a vitamin K-dependent glycoprotein that plays a key role in the blood coagulation process as factor Xa. Factor Xa, along with factor Va, calcium, and phospholipids, coordinates the conversion of prothrombin to thrombin, a key step in the coagulation cascade. Coagulation Factor X/F10 Protein, Human (HEK293, Fc) is the recombinant human-derived Coagulation Factor X/F10 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Coagulation Factor X/F10 Protein, Human (HEK293, Fc) is 457 a.a., with molecular weight of 80-130 & 25 kDa, respectively.
Coagulation Factor IX/F9 Protein, a vital vitamin K-dependent plasma protein, is pivotal in the intrinsic blood coagulation pathway. Its role includes converting factor X into its active form, a process facilitated by Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation Factor IX/F9 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor IX/F9 protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor IX/F9 Protein, Mouse (HEK293, His) is 471 a.a., with molecular weight of 60-95 kDa.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Coagulation Factor XI/F11 protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor XI/F11 Protein, Cynomolgus (HEK293, His) is 607 a.a., with molecular weight of 70-85 kDa.
Coagulation factor XIII B/F13B Proteinas, the B chain of factor XIII, lacks catalytic activity but stabilizes A subunits and regulates thrombin-initiated transglutaminase formation. Functioning as a tetramer with two A chains (F13A1) and two B chains (F13B), it structurally supports the factor XIII complex, emphasizing its regulatory role in blood coagulation, particularly in transglutaminase activation by thrombin. Coagulation factor XIII B/F13B Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor XIII B/F13B protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation factor XIII B/F13B Protein, Human (HEK293, His) is 641 a.a., with molecular weight of 80-90 kDa.
Coagulation Factor III (F3), or Tissue Factor (TF), initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex critically activates factors IX or X through limited proteolysis, initiating the coagulation cascade on the cell surface. F3's interaction with HSPE, inhibited by heparin, promotes the generation of activated factor X, emphasizing its central role in regulating hemostatic processes. Coagulation Factor III/F3 Protein, Canine (HEK293, His) is the recombinant canine-derived Coagulation Factor III/F3 protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor III/F3 Protein, Canine (HEK293, His) is 214 a.a., with molecular weight of 35-45 kDa.
rHucoagulationfactor XIII A chain/F13A, His; coagulationfactor XIII A Chain; coagulationfactor XIIIa; Protein-Glutamine Gamma-Glutamyltransferase A Chain; Transglutaminase A Chain; F13A1; F13A
Coagulation factor XIII A chain is the A chain of factor XIII. As a coagulation factor, Factor XIII A chain alters clot stabilization and bleeding. Factor XIII A chain regulates multiple aspects of wound healing: stabilizes fibrin clots and extracellular matrix, modulates monocyte functions, promote angiogenesis, and upregulates proangiogenic early growth response transcription factor 1. Coagulation factor XIII A/F13A Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor XIII A/F13A protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Coagulation factor XIII A/F13A Protein, Human (HEK293, His) is 694 a.a., with molecular weight of 80-90 kDa.
Factor XIV/PROC protein (or protein C) is an important vitamin K-dependent serine protease that regulates blood clotting.Protein C plays a crucial role in inactivating factors Va and VIIIa and regulating the coagulation cascade in the presence of calcium ions and phospholipids.Coagulation Factor XIV/PROC Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor XIV/PROC protein, expressed by HEK293 , with C-His labeled tag.
Coagulation Factor XIV/PROC is a vital vitamin K-dependent serine protease regulating blood coagulation. Active Protein C inactivates factors Va and VIIIa in the presence of calcium ions and phospholipids, maintaining the intricate balance of coagulation pathways. Its protective effect on endothelial cell barrier function underscores a broader impact on vascular integrity. Coagulation Factor XIV/PROC Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XIV/PROC protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor XIV/PROC Protein, Human (HEK293, His) is 443 a.a., with molecular weight of 56-64 & 45 kDa, respectively.
Tissue factor (TF) initiates blood coagulation by forming a complex with circulating factor VII or VIIa, thus forming the [TF:VIIa] complex. This complex is capable of specific limited proteolysis of factors IX or X and plays a key role in normal hemostasis by initiating the coagulation protease cascade. Tissue Factor Protein, Mouse (HEK293, His) is the recombinant mouse-derived Tissue Factor protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Tissue Factor Protein, Mouse (HEK293, His) is 223 a.a., with molecular weight of 35-42 kDa.
F3 Protein, a cell surface receptor, plays a significant role in regulating blood coagulation and promoting cell adhesion. Dysregulation of F3 Protein has been associated with various disorders, including thrombosis and cancer. Targeting F3 Protein may offer potential therapeutic interventions in these conditions by inhibiting blood clot formation and preventing tumor cell adhesion and metastasis. Tissue Factor Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Tissue Factor protein, expressed by HEK293 , with C-His labeled tag.
Tissue Factor Protein plays a critical role in blood coagulation.It binds to coagulation factors, activating clotting cascades.Tissue Factor Protein interacts with cells, promoting thrombosis and inflammation.Understanding its functions can aid in developing treatments for blood disorders and cardiovascular diseases.Tissue Factor Protein, Rat (HEK293, His) is the recombinant rat-derived Tissue Factor protein, expressed by HEK293 , with C-His labeled tag.
Tissue Factor Protein initiates blood coagulation by binding to coagulation factors. It activates clotting cascades and interacts with cells to promote thrombosis and inflammation. Understanding Tissue Factor Protein's functions is crucial for developing treatments for cardiovascular diseases and blood disorders. Tissue Factor Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived Tissue Factor protein, expressed by HEK293 , with C-His labeled tag. The total length of Tissue Factor Protein, Rabbit (HEK293, His) is 218 a.a., with molecular weight of ~26.4 kDa.
Tissue Factor Protein, Human (HEK293, His) is a recombinant human CD142 expressed in HEK 293 cells with a His tag at the C-terminus. Coagulation Factor III/CD142 Protein is a principal regulator of oncogenic neoangiogenesis and controls therefore the cancerous process.
Tissue Factor Protein, Human (HEK293, Fc) is a recombinant human CD142 expressed in HEK 293 cells with a Fc tag at the C-terminus. Coagulation Factor III/CD142 Protein is a principal regulator of oncogenic neoangiogenesis and controls therefore the cancerous process.
TFPI Protein inhibits factor X (Xa) directly and, in an Xa-dependent manner, hinders the activity of VIIa/tissue factor, possibly by forming a quaternary complex with Xa, TFPI, VIIa, and tissue factor. This multifunctional protein has antithrombotic properties and associates with lipoproteins in plasma, highlighting its crucial role in regulating the coagulation pathway. TFPI Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived TFPI protein, expressed by HEK293 , with N-10*His labeled tag. The total length of TFPI Protein, Rabbit (HEK293, His) is 276 a.a., with molecular weight of 55 kDa.
rHuDiscoidin, CUB and LCCL domain-containing protein 2/ DCBLD2, His; Discoidin; CUB and LCCL domain-containing protein 2; DCBLD2; CUB; LCCL and coagulationfactor V/VIII-homology domains protein 1; Endothelial and smooth muscle cell-derived neuropilin-like protein; DCBLD2; CLCP1; ESDN;
DCBLD2 Protein is a novel platelet membrane receptor that recruits TRAF6 through EGFR phosphorylation and stimulates AKT to promote tumorigenesis. The DCBLD2 Protein has multiple functions during development as well as in vascular and tumor biology, such as influencing cell proliferation and tumorigenesis. DCBLD2 Protein, Human (HEK293, His) is the recombinant human-derived DCBLD2 protein, expressed by HEK293 , with C-6*His labeled tag.
coagulationfactor XIIIa; F13A; F13a1; Fibrin stabilizing factor; A subunit; Fibrinoligase; TGase; Transglutaminase A chain
WB, IHC-P
Human
Factor XIIIa Antibody (YA1631) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1631), targeting Factor XIIIa, with a predicted molecular weight of 83 kDa (observed band size: 83 kDa). Factor XIIIa Antibody (YA1631) can be used for WB, IHC-P experiment in human background.
Factor IX Antibody (YA1353) is a biotin-conjugated non-conjugated IgG antibody, targeting Factor IX, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). Factor IX Antibody (YA1353) can be used for WB experiment in human background.
F2 Antibody is a biotin-conjugated non-conjugated IgG antibody, targeting F2, with a predicted molecular weight of 70 kDa (observed band size: 76 kDa). F2 Antibody can be used for WB, IP experiment in human background.
Activated factor Xa heavy chain; coagulationfactor X; F10; factor Xa; FXA; Prothrombinase; Stuart factor
WB, IHC-P
Human
Factor X Antibody (YA1349) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1349), targeting Factor X, with a predicted molecular weight of 55 kDa (observed band size: 74 kDa). Factor X Antibody (YA1349) can be used for WB, IHC-P experiment in human background.
F3; Tissue factor; TF; coagulationfactor III; Thromboplastin; CD antigen CD142
WB, IHC-P
Human, Mouse, Rat
Tissue Factor Antibody (YA2471) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2471), targeting Tissue Factor, with a predicted molecular weight of 33 kDa (observed band size: 45 kDa). Tissue Factor Antibody (YA2471) can be used for WB, IHC-P experiment in human, mouse, rat background.
PROC; Vitamin K-dependent protein C; Anticoagulant protein C; Autoprothrombin IIA; Blood coagulationfactor XIV
WB
Human
Protein C Antibody (YA2461) is a biotin-conjugated non-conjugated IgG antibody, targeting Protein C, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). Protein C Antibody (YA2461) can be used for WB experiment in human background.
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulationfactor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulationfactor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulationfactor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
Inquiry Online
Your information is safe with us. * Required Fields.
